<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1735">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093664</url>
  </required_header>
  <id_info>
    <org_study_id>AFF004A</org_study_id>
    <nct_id>NCT01093664</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02</brief_title>
  <official_title>Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiris AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiris AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with&#xD;
      regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who&#xD;
      have received the vaccine within the clinical study AFF002.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>July 2010</time_frame>
    <description>Withdrawal criteria (continuation decision) Number of patients who withdraw due to AEs Reason for withdrawal&#xD;
Adverse events (AEs)&#xD;
Serious adverse events (SAEs)&#xD;
Physical and neurological examination&#xD;
Concomitant medication&#xD;
Vital signs (blood pressure, heart rate, respiratory rate, body temperature)&#xD;
Body mass (weight and height)&#xD;
MRI of brain&#xD;
ECG&#xD;
Laboratory assessment (haematology, biochemistry, coagulation, serology and urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological and clinical activity</measure>
    <time_frame>July 2010</time_frame>
    <description>Immunological parameters:&#xD;
- Assessment of the immune response triggered by the vaccine (titre of IgG antibodies specific for the immunizing peptide, N-terminal part of Aβ, (irrelevant peptide serves as specificity control), Aβ itself and KLH as assessed by ELlSA as well as the results of the biacore affinity measurements towards the immunizing peptide and Aβ)&#xD;
Clinical efficacy variables:&#xD;
Cognitive and functional tests, behavioural scales&#xD;
Measurement of quality of life in patients with Alzheimer's disease&#xD;
Investigator's global evaluation scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AFFITOPE AD02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AFFITOPE AD02</intervention_name>
    <description>s.c. injection</description>
    <arm_group_label>AFFITOPE AD02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in AFF002 and AFF004&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of allergy to components of the vaccine, if considered relevant by&#xD;
             the investigator&#xD;
&#xD;
          -  Contraindication for MRI imaging&#xD;
&#xD;
          -  History and/or presence of autoimmune disease, if considered relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Active infectious disease (e.g., Hepatitis B, C)&#xD;
&#xD;
          -  Presence and/or history of Immunodeficiency (e.g., HIV)&#xD;
&#xD;
          -  Significant systemic illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margot Schmitz, Univ. Doz.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ordination Schmitz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordination Schmitz</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Achim Schneeberger, MD</name_title>
    <organization>AFFiRiS AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

